A Safety and Feasibility Study of Mitotane in Prostate Cancer
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
1. The primary objective of this study is to assess the feasibility of treating patients
with metastatic castration resistant prostate cancer with mitotane. Secondary objectives
are to assess safety and tolerability as well as response rate of therapy
2. To assess the toxicity of Mitotane in men with HRPC
3. To assess the relationship between baseline serum adrenal androgens and their response
to Mitotane